The utility of routine surveillance screening with magnetic resonance imaging (MRI) to detect tumour recurrence in children with low-grade central nervous system (CNS) tumours: a systematic review by Stevens SP et al.
Vol.:(0123456789) 
Journal of Neuro-Oncology 
https://doi.org/10.1007/s11060-018-2901-x
TOPIC REVIEW
The utility of routine surveillance screening with magnetic resonance 
imaging (MRI) to detect tumour recurrence in children with low-grade 
central nervous system (CNS) tumours: a systematic review
Simon P. Stevens1 · Caroline Main1 · Simon Bailey2 · Barry Pizer3 · Martin English5 · Robert Phillips6 · Andrew Peet4 · 
Shivaram Avula3 · Sophie Wilne7 · Keith Wheatley1 · Pamela R. Kearns1,5 · Jayne S. Wilson1
Received: 16 February 2018 / Accepted: 12 May 2018 
© The Author(s) 2018
Abstract
Background Magnetic resonance imaging (MRI) is routinely used as a surveillance tool to detect early asymptomatic tumour 
recurrence with a view to improving patient outcomes. This systematic review aimed to assess its utility in children with 
low-grade CNS tumours.
Methods Using standard systematic review methods, twelve databases were searched up to January 2017.
Results Seven retrospective case series studies (n = 370 patients) were included, with average follow-up ranging from 5.6 
to 7 years. No randomised controlled trials (RCTs) were identified. Due to study heterogeneity only a descriptive synthesis 
could be undertaken. Imaging was most frequent in the first year post-surgery (with 2–4 scans) reducing to around half this 
frequency in year two and annually thereafter for the duration of follow-up. Diagnostic yield ranged from 0.25 to 2%. Recur-
rence rates ranged from 5 to 41%, with most recurrences asymptomatic (range 65–100%). Collectively, 56% of recurrences 
had occurred within the first year post-treatment (46% in the first 6-months), 68% by year two and 90% by year five. Follow-
ing recurrence, 90% of patients underwent treatment changes, mainly repeat surgery (72%). Five-year OS ranged from 96 to 
100%, while five-year recurrence-free survival ranged from 67 to 100%. None of the studies reported quality of life measures.
Conclusion This systematic review highlights the paucity of evidence currently available to assess the utility of MRI surveil-
lance despite it being routine clinical practice and costly to patients, their families and healthcare systems. This needs to be 
evaluated within the context of an RCT.
Keywords Systematic review · Magnetic resonance imaging (MRI) · Surveillance · Children · Central nervous system 
(CNS) tumours · Recurrence · Pilocytic astrocytoma · Low grade glioma
Introduction
Paediatric low-grade CNS tumours are an extremely diverse 
group of neoplasms. The likelihood of recurrence is largely a 
function of tumour type, but also varies according to tumour 
location as well as treatment regimens [1].Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s1106 0-018-2901-x) contains 
supplementary material, which is available to authorized users.
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Surveillance neuroimaging is routinely used to detect 
recurrence in children with low-grade CNS tumours in 
the absence of clinical signs and symptoms. The rationale 
behind surveillance is that recurrence detected at a stage 
when there is less disease will be more responsive to treat-
ment and this will result in improved outcomes for patients. 
The scheduling and imaging techniques employed, or sur-
veillance protocols, are loosely based on the biological 
characteristics of the different CNS tumour types, taking 
into account the rate of tumour growth, location and pat-
terns of local and metastatic recurrence [2, 3].
In recent years, magnetic resonance imaging (MRI) 
has replaced computed tomography (CT) as the dominant 
surveillance neuroimaging modality. Its greater imaging 
resolution and multi-planar capability account for its 
superior diagnostic utility, particularly with respect to 
soft tissue neoplasms such as CNS tumours [4]. How-
ever, despite being standard practice, there have been no 
systematic reviews assessing surveillance MRI in this 
patient group.
The aims of this systematic review were to:
1. Assess the utility of surveillance MRI to detect early 
tumour recurrence in children with no new, stable or 
improved neurological signs or symptoms with low-
grade CNS tumours compared to the use of non-routine 
imaging undertaken on presentation with disease signs 
or symptoms and whether this results in improved clini-
cal outcomes for patients and their families;
2. Evaluate the effects of varying MRI screening intervals 
across tumour types and determine the optimum length 
of time for screening post-initial diagnosis;
3. Identify gaps and methodological weaknesses in the 
current evidence base to inform the design of future 
studies.
Methods
This review is part of a series of systematic reviews look-
ing at treatments for paediatric CNS tumours. The project 
included public and patient involvement (PPI), consisting of 
the parents of children with CNS tumours who expressed a 
particular interest in this review question, which was pivotal 
in our decision to undertake the current review.
Standard systematic review methodology aimed at mini-
mising bias was employed and reporting followed the Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines [5]. A detailed account of 
the methodology employed in this review can be found in 
the published protocol, which is also registered with PROS-
PERO (CRD42016036802) [6].
Search strategy
Searches for published studies from 1985 to January 2017 
were undertaken in a number of databases, including MED-
LINE, EMBASE and the Cochrane Library. No language/
publication restrictions or study design filters were applied 
(see Online Resource 1 for search strategy and databases 
searched). Reference lists of included studies were citation-
checked and experts in the field consulted for published stud-
ies not retrieved by the electronic searches.
Study selection
The following inclusion and exclusion criteria were applied:
Population Children and young adults (age up to 
25 years) with diagnoses of any type of low grade (i.e. WHO 
grade I and II) CNS tumour who had either no new, stable 
or improved neurological signs or symptoms at the time of 
study recruitment.
Intervention Routine interval follow-up MRI scans con-
ducted at any screening interval determined within the pri-
mary study. Studies reporting CT scans were excluded.
Outcomes Outcome measures included recurrence rates 
(by study, tumour type, location and extent of resection), 
diagnostic yield of imaging, timing of recurrence, change in 
patient management post-recurrence, overall survival (OS), 
surrogate survival measures (i.e. recurrence-free survival 
(RFS) and progression-free survival (PFS)) and quality of 
life.
Patients were deemed to have experienced a recurrence 
if, after undergoing complete surgical removal of their pri-
mary tumour [i.e. achieving a gross total resection (GTR)], 
evidence of tumour was captured on a subsequent MRI scan. 
Patients were deemed to have experienced progressive dis-
ease if, after undergoing incomplete surgical removal of 
their primary tumour [i.e. achieving a sub-total resection 
(STR)], evidence of a significant increase in the size of the 
tumour was captured on a subsequent MRI scan. However, 
for the purposes of this paper, we use the term ‘recurrence’ 
to cover both recurrence in GTR and progression in STR 
patients.
All of the studies in this review reported patient out-
comes in terms of whether or not patients were asympto-
matic at recurrence. However, children undergoing surveil-
lance imaging for detection of recurrent disease will often 
be asymptomatic from the recurrence but may have some 
neurologic sequelae from their tumour and/or its treatment. 
This was the reason for characterising patients as having 
either no new, stable or improved neurological signs or 
symptoms.
Study designs Randomised controlled trials (RCTs) and 
non-randomised comparative studies were initially sought. 
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However, as no such studies were identified the review was 
extended to include observational studies, such as case 
series studies. Single case reports, letters or editorials were 
excluded.
Study selection was undertaken by two independent 
reviewers. Citations marked for inclusion on the basis of 
title and abstract underwent full text assessment. Disagree-
ments were resolved by discussion (see Online Resource 2 
for details of excluded studies).
Data extraction and risk of bias assessment
Data was extracted by one reviewer and checked by a sec-
ond and recorded on a standardised pro-forma (see Online 
Resource 3). Risk of bias was conducted by two review-
ers and assessed at the study level using a six-point tool 
devised by the Centre for Reviews and Dissemination 
(York; CRD) specifically designed to assess bias in case 
series studies [7].
Statistical analysis
Due to the design of the studies included in the review and 
the heterogeneity of outcomes reported, only a descriptive 
analysis of the data was possible.
Results
Quantity of the research
From the electronic database searches, 28 publications 
were considered potentially relevant to this review, with 
an additional 13 identified from citation checking. On full 
text examination, 34 publications did not meet the inclusion 
criteria including 14 surveillance imaging studies which 
employed both CT and MRI but failed to report results 
separately for MRI. No RCTs or prospective comparative 
studies were identified. Seven retrospective case series were 
included in the review [8–14] (see Fig. 1 for the PRISMA 
flow diagram).
Quality of the research
All seven studies were undertaken at single centre institu-
tions. Study samples were small but appeared to be rep-
resentative of the relevant population, i.e. children with 
low-grade CNS tumours undergoing surveillance imaging 
using MRI to detect recurrence. In all studies, inclusion and 
exclusion criteria for each study were explicitly stated. Gen-
erally, participants were at a similar time point in the course 
of their disease in that all had undergone resection of their 
primary tumour, whether a GTR or STR. Definitions of GTR 
and STR were provided although definitions varied between 
studies (see Online Resource 4 for definitions table). No 
studies containing STR patients reported the size/extent of 
residual tumour. Duration of follow-up was reported in five 
studies [9, 11–14]. Assessment of outcomes using objec-
tive criteria was variable. The definition for radiographic 
recurrence was provided in all but two studies [10, 12] but 
again definitions varied between studies. All but one study 
[13] reported details of the change in patient management/
treatment post-recurrence. Definitions of survival outcome 
measures were provided in only half of the studies report-
ing survival, with one study failing to define OS [8] and 
one RFS [12] (see Online Resource 5 for quality assessment 
table).
Description of included studies
The seven studies were published between 2001 and 2016 
with six published since 2009 [9–14]. Five studies were 
undertaken in the USA [8, 9, 11–13], one in Canada [14] 
and one in Australia [10]. The studies (overall n = 469 
patients) were comprised of six low grade tumour studies 
[9–14] and one with a mix of low and high-grade tumours 
[8]. The total number of patients in the low-grade studies 
was 357 with a mean sample size of 60. Mean age at diag-
nosis was 7.5 years, 48% of patients were male and 75% of 
tumours were located in the posterior fossa. Median follow-
up ranged from 5.6 to 7 years. Three studies [9, 11, 13] 
explicitly excluded children with Neurofibromatosis Type 
1, with the remaining studies providing no details of the 
NF1 status of their study populations. At the commencement 
of surveillance imaging, none of the patients had relapsed 
disease (See Table 1).
The six low-grade tumour studies included patients with 
the following tumour types: pilocytic astrocytoma (n = 297), 
ganglioglioma (n = 22), dysembryoplastic neuroepithelial 
tumour (DNET) (n = 6), glioneuronal tumours (n = 1), non-
pilocytic astrocytoma/diffuse fibrillary astrocytoma (DFA) 
(n = 18), optic glioma (n = 7), oligodendroglioma (n = 3) and 
‘other’ astrocytoma (n = 3).
Korones [8]
This was the only mixed grade tumour study but it also 
differed from the other studies in that it did not provide a 
breakdown of patients at the beginning of the study, instead 
reporting only the number of recurrences by tumour type. 
Thirteen LGG patients recurred (11 astrocytomas and two 
gangliogliomas). However, as the number of non-recurrent 
LGG patients was not reported, recurrence rates were not 
calculable and therefore data from this study is not compa-
rable with that from the other studies. Of the 13 recurrences, 
ten patients (nine astrocytoma and one ganglioglioma) 
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were asymptomatic at recurrence giving a diagnostic yield 
of scanning of 3.7% (or one recurrence detected every 27 
scans). Recurrent patients were scanned with a frequency of 
one scan every 5.3 months. Median time to recurrence was 
2.3 years and OS was 100%. Neither outcome was reported 
by tumour type.
MRI protocols
Four studies reported details regarding MRI scanners used, 
image sequences, weighting and contrast enhancement [9, 
11, 13, 14]. (For details, see Table 1).
Electronic records potentially 
relevant to the 
MRI topic (N=28)
Records identified through 
database searching for all 
topics (N=10,072)
Additional records identified from 
searching other sources 
(N=13 from reference checking)
SC
R
E
E
N
IN
G
Records screened
(N=41)
Records excluded (N=0)
E
L
IG
IB
IL
IT
Y
Publications excluded on the basis of full-text 
screening (N=34) including:
• Non surveillance imaging studies (n=18)
• Studies using both CT and MRI at baseline  
and/or follow-up with results not reported 
separately by imaging modality (n=14)
• Surveillance MRI studies in children with 
high-grade tumours (n=2)
ID
E
N
T
IF
IC
A
T
IO
N
Records excluded 
(N=10,044)
Full-text publications 
assessed for eligibility
(N=41)
IN
C
LU
D
ED Included Studies
(N=7)
Fig. 1  PRISMA diagram of flow of studies through the selection process
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Imaging schedules/frequency of imaging
Whilst the reporting of the frequency of scanning varied 
between studies, with some [9–11] reporting scanning inter-
vals and others [9, 11, 12] reporting the number of scans 
per patient, a discernible pattern emerged whereby imaging 
was at its most frequent within the first year (2–4 follow-up 
scans), reducing to around half this frequency in year two 
and then becoming annual thereafter for the duration of fol-
low-up. Vassilyadi et al. [14] reported frequency in terms of 
scanning intervals by extent of resection, with STR patients 
undergoing almost twice as many scans as GTR patients 
(one scan every 6 months vs 11 months respectively) while 
Udaka et al. [13] reported intervals with respect to recurrent 
patients only (1 scan every 3.5 months) rather than the total 
number of patients at the beginning of the study.
Five studies reported the average number of MRI scans 
per patient for the duration of follow-up [9, 11–14], ranging 
from six [11] to 17 scans [13]. This however is somewhat 
misleading as studies were inconsistent in terms of report-
ing as Udaka et al. [13] reported the number of scans for 
recurrent patients only, Alford et al. [9] the average num-
ber of scans for GTR patients (median nine) and Dodgshun 
et al. [10] stated the recommendations pertaining at their 
institution at the time of publication (nine scans in the first 
5 years).
Vassilyadi et al. [14] reported the average number of 
scans by tumour sub-group with the median for PA patients 
comparable to that for non-PA patients (seven vs eight/nine 
respectively). The distribution of scans over the follow-up 
period was not reported.
Rates of recurrence
Overall, of the total of 357 patients, 98 cases (24%) of recur-
rence occurred. Recurrence rates by study ranged from 5 to 
41% of patients. Five studies reported recurrence by sympto-
matic status at recurrence, of which 0–35% of patients were 
symptomatic while 65–100% of patients were asymptomatic 
[10–14]. (See Table 2).
Recurrence rates by tumour type
Of 297 patients with PA, 70 (24%) recurred with recurrence 
rates across the six studies ranging from 5% [10] to 47% 
[13]. Of 22 ganglioglioma [12, 13], six DNET [12] and 
13 non-PA/DFA [14] patients, five, one and one patients 
recurred respectively. Udaka, the only study to report both 
first and subsequent recurrences, reported eight recurrences 
across three unspecified PA patients [13]. (See Table 3).
Asymptomatic recurrence rates for PA were calculable in 
four studies, ranging from 82 to 100% [10–12, 14]. Across 
the four studies, 96% of recurrences were asymptomatic. 
Kim reported that the three recurrences of ganglioglioma 
and one recurrence of DNET were all asymptomatic at 
recurrence [12]. The patient with progressive non-PA was 
asymptomatic at recurrence [14].
There were no recurrences observed in patients with 
glioneuronal tumour, optic glioma and oligodendroglioma 
although the number of patients with each of these tumour 
types was so small that no inferences should be drawn 
regarding recurrence in these patients.
Recurrence rates by tumour site
While most studies reported patients by both tumour type 
and location, most outcomes, including recurrence, were 
reported by tumour type alone and therefore it was not pos-
sible to discern the effect of tumour location on recurrence. 
Only Dodgshun et al. [10], with nine of 67 PAs located 
supratentorially, reported that there was ‘no difference in 
recurrence rate with regard to tumour site (p = 0.37).’
Recurrence rates by extent of resection
The three studies consisting solely of GTR patients reported 
recurrence rates of 4% (n = 3/67), 28% (n = 11/40) and 19% 
(n = 13/67) respectively [10–12]. Three of the four stud-
ies with both GTR and STR patients reported recurrence 
rates for GTR patients of 15% (n = 6/41), 24% (n = 9/38) 
and 0% (n = 0/19) respectively and rates of recurrence for 
STR patients of 33% (n = 4/12), 55% (n = 35/64) and 22% 
(n = 2/9) respectively [9, 13, 14] (See Table 4).
Diagnostic yield of imaging
The diagnostic yield of MRI, or the number of scans identi-
fying recurrence as a proportion of total scans, was reported 
in three studies [9, 10, 14]. For Alford, diagnostic yield was 
2% (i.e. one recurrence detected every 50 scans) based on 6 
of 41 predominantly GTR patients [9]. As the symptomatic 
status of recurrent patients was not reported, diagnostic yield 
by symptomatic status was not calculable. For Dodgshun, 
diagnostic yield was 0.25% (one asymptomatic recurrence 
detected with 399 scans) based on 33 patients with at least 
5 years follow-up [10]. For Vassilyadi, diagnostic yield was 
1% (two asymptomatic recurrences detected with 216 scans) 
in STR patients [14].
Time to recurrence
Five studies [8, 10–14] reported average time to recurrence 
post-primary treatment ranging from 0.33 [14] to 2.33 years 
[8]. (See Table 2). In two studies, recurrence was 100% 
asymptomatic with median times to recurrence of 1.9 and 
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1.0 years respectively [10, 12]. Neither of the studies con-
taining mixed low-grade tumour types reported median time 
to recurrence by tumour type [12, 13].
Time to recurrence by extent of resection
Three studies with exclusively GTR patients reported 
median times to recurrence of 0.53 [11], 1.0 [12] and 1.9 
[10] years respectively. Of the three studies containing both 
GTR and STR patients, two reported median times to recur-
rence of 2.28 [13] and 0.33 years [14] respectively. Only 
Alford et al. [9] reported median time to recurrence solely 
by extent of resection [GTR 0.64 vs STR 0.42 years respec-
tively (p < 0.0001)].
Timing of recurrences
Five studies provided data on the timing of recurrences 
post-diagnosis/primary treatment [10–14]. Collectively, 
56% of recurrences took place within the first year post-
primary treatment (with 46% of these within the first six 
months), 68% by year two and 90% by year five. Neither of 
the studies with mixed tumour populations reported timing 
of recurrences by tumour type [12, 13].
Patient management post‑recurrence
Four studies reported details of patient management fol-
lowing recurrence with respect to 29 patients, 28 of whom 
Table 3  Recurrence rates and timing of recurrence by tumour type
Asymp. asymptomatic, GTR gross total resection, N number of patients in study, NR not reported, STR sub-total resection, Symp. symptomatic
a Korones et al. [8] was the only study which did not provide a breakdown of the patients at the beginning of the study in terms of tumour type 
and, as such, the number of recurrences in this study (n = 13) has not been taken into account when calculating the percentage of the total num-
ber of patients at baseline with each tumour type which went on to experience a recurrence
Study [ref] N of pts Patients with recurrent/progressive 
disease: n (%)
Median time to recurrence:
years (range)
Median time to recur-
rence:
years (range)
Total Symp Asympt Sympt Asympt
(a) Low-grade tumour studies
Pilocytic astrocytoma
 Alford et al. [9] 53 10 (19) NR NR GTR pts (n = 6)
0.64  (0.26–6.42)
STR pts (n = 4)
5.23  (range NR)
NR NR
 Dodgshun et al. [10] 67 3 (5) 0 (0) 3 (100) 1.9  (0.75–2.75) 0 1.9
(07.5–2.75)
 Dorward et al. [11] 40 11 (28) 1 (9) 10 (91) 0.53  (0.17–4.02) NR NR
 Kim et al. [12] 46 9 (20) 0 (0) 9 (100) NR NR NR
 Udaka et al. [13] 76 36 (47) NR NR NR NR NR
 Vassilyadi et al. [14] 15 1 (7) 0 (0) 1 (100) 0.25 0 0.25
Totals 297 70 (24) 1 (4) 23 (96)
Diffuse fibrillary astrocytoma
 Vassilyadi et al. [14] 13 1 (8) 0 (0) 1 (100) 0.42 0 0.42
Other astrocytoma (WHO 
grade not specified)
 Udaka et al. [13] 3 8 (267) NR NR NR NR NR
Ganglioglioma
 Kim et al. [12] 14 3 (21) 0 3 (100) NR NR NR
 Udaka et al. [13] 8 2 (25) NR NR NR NR NR
Totals 22 5 (23) 0 3 (100)
Dysembryoplastic neuroepithelial tumours (DNET)
 Kim et al. [12] 6 1 (17) 0 1 (100) NR NR NR
(b) Mixed-grade tumour study (Korones)
Other astrocytoma (WHO 
grade not specified)
11a 2 (18) 9 (82) NR NR NR
Ganglioglioma 2 1 (50) 1 (50) NR NR NR
Journal of Neuro-Oncology 
1 3
were asymptomatic [10–12, 14]. Twenty-six patients under-
went a change in their management including repeat sur-
gery (n = 21), chemotherapy (n = 2), radiotherapy (n = 2) 
and radiosurgery (n = 1). The remaining three patients were 
observed.
Survival
All but two studies reported some type of survival outcome 
[9, 14].
Overall survival (OS)
Four studies reported OS up until the time of report-
ing [10–13]. In two studies of PA [10, 11] OS was100% and 
in the two mixed tumour studies [12, 13] OS was 96 and 
100% respectively, all measured from recurrence.
Surrogate survival outcomes
Four studies reported surrogate survival outcomes [10–13]. 
Dodgshun et al. [10] reported 5-year EFS of 95% (95% CI 
90–100%). Dorward reported RFS by evidence of ‘nodu-
lar enhancement’ on surveillance MRI within the first 3–6 
months, with both the 5- and 10-year RFS for PA patients 
whose scans lacked evidence of nodular enhancement of 
90% compared to patients whose scans evidenced nodular 
enhancement of 44 and 22% respectively [11]. Kim reported 
2- and 5-year RFS for 67 patients of 90% and 82% respec-
tively, as well as RFS by tumour type, with 2- and 5-year 
RFS for PA, ganglioglioma and DNET of 87 and 82, 93 and 
85 and 100 and 67% respectively [12].
Udaka reported median PFS for all 102 patients (4.7 years) 
and separately for patients with PA (4.2 years) who repre-
sented 75% of the study population [13]. Median PFS for GTR 
patients was significantly greater than STR/biopsy patients 
[not reached versus 2.1 years respectively (p = 0.012)]. Udaka 
also found that while recurrence was reduced in GTR patients, 
it occurred earlier compared to those with less than total 
resection (16.6 vs 25.8 months, respectively).
Quality of survival
None of the studies reported quality of survival of the chil-
dren and their families.
Discussion
This systematic review was borne out of discussions between 
the project team and the PPI group, which consisted largely 
of mothers of children with CNS tumours. Of particular 
interest to the PPI group was surveillance scanning and its 
frequency. They remarked that scanning was a significant 
and time-consuming part of their lives and a major source 
of anxiety to the whole family before, during and after each 
scan. However, they were unanimous that scanning was 
something they were prepared to endure so long as this was 
an evidence-based practice that ultimately benefitted their 
children. They were surprised to learn that, despite being 
routine practice, there are no internationally adopted guide-
lines for the frequency and duration of surveillance MRI in 
paediatric CNS tumours. This issue is not only important to 
patients and their families but also to health care systems 
such as the NHS in terms of direct and indirect healthcare 
Table 4  Breakdown of low-
grade tumour patients by extent 
of resection
GTR gross total resection, N/A not applicable, Pts patients, N number of patients in study, N total number 
of patients in study, NR not reported, NR not reported, Rec n number of recurrent patients, STR sub-total 
resection
a GTR/indeterminate
Author (year) [ref] N Rec
N
GTR 
n (%)
STR
n (%)
N/A
All pts Rec pts All pts Rec pts
GTR pts only
Dodgshun et al. (2016) [10] 67 3 67 (100) 3 (4) N/A N/A N/A
Dorward et al. (2010) [11] 40 11 40 (100) 11 (28) N/A N/A N/A
Kim et al. (2014) [12] 67 13 67 (100) 13 (19) N/A N/A N/A
GTR and STR pts
Alford et al. (2016) [9] 53 10 41a (77) 6 (15) 12 (23) 4 (33) N/A
Korones et al. (2014) [8] NR – NR NR NR NR NR
Udaka et al. (2013) [13] 102 46 38 (37) 9 (24) 64 (63) 35 (55) 2 (4)
Vassilyadi et al. (2009) [14] 28 2 19 (68) 0 (0) 9 (32) 2 (22) N/A
Totals 357 85 272 (76) 42 (15) 85 (24) 41 (48) 2 (3)
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costs. A surveillance imaging programme needs to detect 
recurrent disease ahead of onset of signs/symptoms and to 
result in changes in patient management which bestow a 
long-term clinical benefit in terms of improved patient out-
comes (i.e. reduced mortality and/or improved quality of 
survival). Ultimately, the assessment of both the benefits and 
costs of this practice should be based on research evidence 
and this is what prompted us to undertake the current review.
Six low-grade tumour surveillance imaging studies were 
excluded from the review as they employed both CT and 
MRI as surveillance imaging modalities but did not report 
results separately by modality [15–20]. No comparative 
studies assessing the effectiveness of routine surveillance 
screening with MRI were identified. The evidence base to 
guide the clinical practice of surveillance MRI for children 
with low-grade CNS tumours consisted of seven small ret-
rospective, single arm observational studies in which data—
acquired for clinical purposes rather than assessment of 
surveillance imaging protocols—was analysed to determine 
the optimal frequency and/or duration of surveillance MRI. 
Six of these studies consisted solely of patients (n = 357) 
with low-grade CNS tumours while one study, comprising 
a mixture of low- and high-grade tumour patients (n = 112), 
reported on 13 low-grade tumour patients [8]. In all stud-
ies, MRI was employed exclusively as the imaging modal-
ity with all of the patients having undergone surgery as a 
primary treatment, achieving either GTR or STR. For all 
studies, both the number and rates of recurrence were low, 
with the majority of recurrences diagnosed asymptomati-
cally via surveillance MRI and tending to occur within the 
first 2 years following primary treatment, suggesting there 
may be scope for reducing the number and frequency of 
later scans (10% of recurrences occurred post-five years, 
although patient characteristics of these individuals were not 
described). The extent of initial resection also appeared to 
be associated with recurrence, with patients achieving GTR 
significantly less likely to experience recurrence.
Although all seven studies reported essentially simi-
lar results, study authors differed in their interpretation, 
leading to opposing conclusions regarding the optimal fre-
quency and/or duration of surveillance with respect to GTR 
patients (see Online Resource 6). For example, Alford et al. 
[9] concluded that frequent imaging of GTR patients may 
be unwarranted beyond the radiological confirmation of 
GTR documented on two consecutive scans separated by at 
least 3 months; likewise the study by Vassilyadi et al. [14] 
concluded that GTR patients may not benefit from surveil-
lance, although this was based solely on recurrences in two 
STR patients. Conversely, Udaka et al. [13] advised cau-
tion, recommending surveillance up to 5 years, irrespec-
tive of the extent of resection. Similarly Dorward, despite 
identifying associations predictive of recurrence in GTR 
patients (p < 0.05), also erred on the side of caution, albeit 
based on limited data (i.e. one delayed recurrence) [11]. 
Both Dodgshun et al. [10] and Kim et al. [12], based on the 
timing of recurrences post-diagnosis, suggested reduced 
imaging schedules but argued that long-term imaging (5 
and 10 years respectively) for GTR patients was necessary 
although, again, this was based on a very small number of 
recurrences—three and 13 recurrences respectively. Over-
all, it is interesting to note that all of these conclusions and 
recommendations were based on low recurrence numbers, 
ranging from 0 [14] to 13 [12].
As demonstrated by the study authors, drawing conclu-
sions from these studies is problematic. The potential for 
bias with case series studies is considerable making any 
conclusions from this review highly tentative and to be 
viewed with extreme caution. For instance, patient popula-
tions across the studies were highly selected with the main 
patient group being children with posterior fossa PA that 
had been completely resected. Half the studies excluded 
patients with low-grade tumour predisposition syndromes 
such as NF1 and tuberous sclerosis [9, 11, 13]. One study 
[13] differed from the others by including a large number 
of patients with low grade gliomas at all sites who had 
immediate adjuvant therapy post-surgery, making them a 
population with a significantly higher risk of recurrence. 
All of this selection bias is likely to skew the results of this 
review. The review question needs to be properly investi-
gated within an RCT. Of particular importance in paediat-
ric low-grade tumour studies, where survival is generally 
excellent, patient-reported quality of survival should be a 
priority: none of the studies reported this outcome. Future 
trials should also examine potential adverse events result-
ing from the repeated administration of contrast materials 
(e.g. Gadolinium [21]) and in younger children, anaesthe-
sia and sedatives. Although an RCT would be challenging 
to design and conduct, the results of this review demon-
strate that we are at equipoise as to the optimum scanning 
regimen. Scanning is a vital part of the treatment pathway 
for children with CNS tumours and has the potential to 
improve survival but also has risks associated with it. Its 
optimum use therefore needs to be established.
To conclude, despite the existence of various consensus 
recommendations [22, 23], this systematic review did not 
identify any studies that were able to inform best prac-
tice as to the frequency or duration of surveillance MRI 
in asymptomatic children with LGG. The findings could 
however inform the development of future clinical trials, 
particularly regarding scanning frequency and duration.
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